Comparative Efficacy of Captopril and Losartan in the Management of Hypertension Secondary to Chronic Kidney Disease in the Pediatric Population.
European Journal of Clinical Pharmacy · 22.12.2025 · 7 (1) · 8083-8089
DOI: 10.61336/ejcp/25-08-495 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacy, online erschienen am 22.12.2025.
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) in children is a progressive condition associated with multiple complications, among which hypertension is one of the most frequent and clinically significant. Chronic hypertension increases cardiovascular morbidity and death and speeds up renal deterioration (1,2). Therefore, increasing renal outcomes and overall survival requires effective blood pressure control. Angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACE inhibitors) are common pharmacological treatments; however, there is still little comparative data in pediatric populations.
Objective
To compare the efficacy of captopril and losartan in the management of hypertension among pediatric patients with chronic kidney disease. Methodology: This randomized controlled experiment was performed in the Department of Pediatrics at Khyber Teaching Hospital in Peshawar for a duration of six months. A total of 380 children aged 3 to 13 years with chronic kidney disease and hypertension were included. Patients were randomized into two cohorts: Group A got losartan (0.7 mg/kg once daily), while Group B received captopril (0.5 mg/kg twice daily). Baseline blood pressure was documented, and further readings were conducted after 6 weeks. Efficacy was characterized by a decrease in blood pressure of ≥10 mmHg. Data were examined using SPSS version 25, with p < 0.05 being statistically significant.
Results
The mean age of participants was 8.1 ± 2.9 years, with a slight male predominance (57.4%). After 6 weeks of treatment, efficacy was achieved in 68.4% of patients in the losartan group compared to 54.2% in the captopril group. The difference was statistically significant (p = 0.004). Losartan also demonstrated a greater mean reduction in blood pressure.
Conclusion
Losartan demonstrates superior efficacy compared to captopril in managing hypertension in juvenile patients with chronic kidney disease and may be regarded as a preferable treatment choice.
Zitieren
APA
(2025). Comparative Efficacy of Captopril and Losartan in the Management of Hypertension Secondary to Chronic Kidney Disease in the Pediatric Population. European Journal of Clinical Pharmacy, 7(1), 8083-8089. https://doi.org/10.61336/ejcp/25-08-495
Vancouver
Comparative Efficacy of Captopril and Losartan in the Management of Hypertension Secondary to Chronic Kidney Disease in the Pediatric Population. European Journal of Clinical Pharmacy. 2025;7(1):8083-8089. doi:10.61336/ejcp/25-08-495
BibTeX
@article{euvimed2025,
title = {Comparative Efficacy of Captopril and Losartan in the Management of Hypertension Secondary to Chronic Kidney Disease in the Pediatric Population},
journal = {European Journal of Clinical Pharmacy},
year = {2025},
volume = {7},
number = {1},
pages = {8083--8089},
doi = {10.61336/ejcp/25-08-495}
}
EUVIMED